Mortgage technology specialist Ellie Mae (NYSE:ELLI) has agreed to be acquired by Thoma Bravo, a private equity firm. As of 11:52 a.m. EST, shares of the company were up 21%.
So whatThe acquisition is an all-cash transaction, and upon the closing of the deal, Ellie Mae shareholders will receive $99 in cash for each share of stock they own. This is a premium of about 21% to the previous day's close, after an already strong start to 2019, although it's still well below the 52-week high of $116.90.
Image source: Getty Images.
It may seem odd that the acquisition price of Ellie Mae is $99 per share and the stock spiked to slightly higher than $99 following the announcement. Generally speaking, acquisition targets in these situations will spike, but to a price somewhat lower than the buyout price in order to compensate for the regulatory risk that the deal won't get done.
Top Stocks To Buy For 2019: Nektar Therapeutics(NKTR)
Advisors' Opinion:- [By Stephan Byrd]
TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.
- [By ]
Another interesting candidate from the list is Nektar Therapeutics (Nasdaq: NKTR). The biopharmaceutical company has a handful of drug developments in the immuno-oncology marketplace with its lead candidate being NKTR-214 -- a drug that stimulates a cancer patient's own immune system to fight cancer.
- [By Chris Lange]
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday's session after the company released preliminary data from its early stage cancer study. The preliminary results were presented at the 2018 American Society of Clinical Oncology (ASCO) over the weekend.
- [By Dan Caplinger]
The stock market finished strong on Friday, celebrating the good news on the macroeconomic front that came in this morning's U.S. employment report. Unemployment dropped to its lowest level in years, with a greater number of new jobs created than those watching the market had expected. Overall, investors seem ready to buy at the first sign of good news, and that helped power major benchmarks to gains of roughly 1%. Some stocks did even better. Nektar Therapeutics (NASDAQ:NKTR), Ambac Financial Group (NASDAQ:AMBC), and Zuora (NYSE:ZUO) were among the best performers on the day. Here's why they did so well.
- [By Cory Renauer]
Bristol-Myers Squibb (NYSE:BMY) has placed a lot of chips on its partnership with Nektar Therapeutics (NASDAQ:NKTR), encouraging plenty of investors to shovel money at the smaller biotech.
Top Stocks To Buy For 2019: Travelzoo Inc.(TZOO)
Advisors' Opinion:- [By Ethan Ryder]
Travelzoo (NASDAQ:TZOO) major shareholder Azzurro Capital Inc sold 69,758 shares of Travelzoo stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $18.13, for a total transaction of $1,264,712.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
- [By Lisa Levin]
Shares of Travelzoo (NASDAQ: TZOO) got a boost, shooting up 30 percent to $10.16 following strong Q1 results.
Six Flags Entertainment Corporation (NYSE: SIX) shares were also up, gaining 8 percent to $64.01 as the company posted a narrower-than-expected loss for its first quarter.
- [By Lisa Levin]
Shares of Travelzoo (NASDAQ: TZOO) got a boost, shooting up 25 percent to $9.70 following strong Q1 results.
Six Flags Entertainment Corporation (NYSE: SIX) shares were also up, gaining 9 percent to $64.54 as the company posted a narrower-than-expected loss for its first quarter.
- [By Max Byerly]
Headlines about Travelzoo (NASDAQ:TZOO) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Travelzoo earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the information services provider an impact score of 45.7844951553237 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Top Stocks To Buy For 2019: First Financial Corporation Indiana(THFF)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on First Financial (THFF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
ValuEngine downgraded shares of First Financial Co. Indiana (NASDAQ:THFF) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.
- [By Ethan Ryder]
BidaskClub upgraded shares of First Financial (NASDAQ:THFF) from a buy rating to a strong-buy rating in a research report released on Thursday.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research raised First Financial from a sell rating to a buy rating and set a $51.00 price objective on the stock in a research report on Thursday, June 28th. ValuEngine raised First Financial from a sell rating to a hold rating in a research report on Tuesday, June 26th.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on First Financial (THFF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
BidaskClub downgraded shares of First Financial Co. Indiana (NASDAQ:THFF) from a hold rating to a sell rating in a report issued on Wednesday morning.
Top Stocks To Buy For 2019: ATRION Corporation(ATRI)
Advisors' Opinion:- [By Shane Hupp]
BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a strong sell rating to a sell rating in a report issued on Thursday morning.
Shares of ATRI stock opened at $604.05 on Thursday. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of 31.94 and a beta of 0.63. Atrion has a 52 week low of $516.85 and a 52 week high of $694.00.
- [By Stephan Byrd]
ATRION (NASDAQ: ATRI) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Top Stocks To Buy For 2019: Catalent, Inc.(CTLT)
Advisors' Opinion:- [By Max Byerly]
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Motley Fool Transcribers]
Catalent Inc (NYSE:CTLT)Q2 2019 Earnings Conference CallFeb. 05, 2019, 8:15 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Logan Wallace]
Catalent Inc (NYSE:CTLT) – Investment analysts at Piper Jaffray Companies reduced their Q2 2019 earnings per share (EPS) estimates for Catalent in a research note issued on Tuesday, August 28th. Piper Jaffray Companies analyst S. Wieland now anticipates that the company will post earnings of $0.36 per share for the quarter, down from their prior forecast of $0.42. Piper Jaffray Companies also issued estimates for Catalent’s Q3 2019 earnings at $0.40 EPS, Q4 2019 earnings at $0.68 EPS and FY2019 earnings at $1.71 EPS.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Catalent (NYSE:CTLT) SVP Steven L. Fasman sold 2,252 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total transaction of $94,088.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
- [By Logan Wallace]
SG Americas Securities LLC decreased its holdings in shares of Catalent (NYSE:CTLT) by 19.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,152 shares of the company’s stock after selling 7,832 shares during the quarter. SG Americas Securities LLC’s holdings in Catalent were worth $1,320,000 as of its most recent SEC filing.
No comments:
Post a Comment